Skip to main content


We're creating a new version of this page. See preview

  • Research article
  • Open Access
  • Open Peer Review

Invasive bacterial co-infection in African children with Plasmodium falciparum malaria: a systematic review

BMC Medicine201412:31

  • Received: 22 February 2013
  • Accepted: 21 January 2014
  • Published:
Open Peer Review reports



Severe malaria remains a major cause of pediatric hospital admission across Africa. Invasive bacterial infection (IBI) is a recognized complication of Plasmodium falciparum malaria, resulting in a substantially worse outcome. Whether a biological relationship exists between malaria infection and IBI susceptibility remains unclear. We, therefore, examined the extent, nature and evidence of this association.


We conducted a systematic search in August 2012 of three major scientific databases, PubMed, Embase and Africa Wide Information, for articles describing bacterial infection among children with P. falciparum malaria using the search string ‘(malaria OR plasmodium) AND (bacteria OR bacterial OR bacteremia OR bacteraemia OR sepsis OR septicaemia OR septicemia).’ Eligiblity criteria also included studies of children hospitalized with malaria or outpatient attendances in sub-Saharan Africa.


A total of 25 studies across 11 African countries fulfilled our criteria. They comprised twenty cohort analyses, two randomized controlled trials and three prospective epidemiological studies. In the meta-analysis of 7,208 children with severe malaria the mean prevalence of IBI was 6.4% (95% confidence interval (CI) 5.81 to 6.98%). In a further meta-analysis of 20,889 children hospitalised with all-severity malaria and 27,641 children with non-malarial febrile illness the mean prevalence of IBI was 5.58 (95% CI 5.5 to 5.66%) in children with malaria and 7.77% (95% CI 7.72 to 7.83%) in non-malaria illness. Ten studies reported mortality stratified by IBI. Case fatality was higher at 81 of 336, 24.1% (95% CI 18.9 to 29.4) in children with malaria/IBI co-infection compared to 585 of 5,760, 10.2% (95% CI 9.3 to 10.98) with malaria alone. Enteric gram-negative organisms were over-represented in malaria cases, non-typhoidal Salmonellae being the most commonest isolate. There was weak evidence indicating IBI was more common in the severe anemia manifestation of severe malaria.


The accumulated evidence suggests that children with recent or acute malaria are at risk of bacterial infection, which results in an increased risk of mortality. Characterising the exact nature of this association is challenging due to the paucity of appropriate severity-matched controls and the heterogeneous data. Further research to define those at greatest risk is necessary to target antimicrobial treatment.


  • Severe malaria
  • Invasive bacterial infection
  • Gram-negative organisms
  • Children
  • Mortality
  • Epidemiology
  • Africa


Malaria remains a leading cause of childhood morbidity and mortality worldwide, accounting for 7% of deaths in children younger than five years of age [1]. In the past few years two of the largest clinical trials ever conducted in African children with severe malaria (SM) have concluded, both holding major implications for treatment guidelines [2, 3]. With the introduction of artesunate in sub-Saharan Africa (sSA), baseline mortality in children with SM will at best be between 6% to 8.5% but likely to be substantially higher outside the framework of Good Clinical Practice-run trials. Understanding the key correlates of poor outcome may identify future targets for additional definitive or adjunctive treatments.

Over time there has been a piecemeal accumulation of data indicating that children with Plasmodium falciparum malaria are at risk of invasive bacterial infection (IBI). Blood stream infection, largely secondary to enteric Gram-negative organisms (EGNOs), with a predominance of non-typhoidal salmonella (NTS) species, has been widely reported as a complication of severe malaria. However, it remains uncertain whether malaria infection is a risk factor for invasive bacterial disease since the majority of children in malaria-endemic Africa are frequently infected by P. falciparum throughout childhood and only a minority will develop severe disease. A sub-analysis within a comprehensive systematic review of blood stream infections in Africa indicated that 6.5% of 11,814 malaria infections had concomitant bacteremia [4]. Which children are at greatest risk of developing dual infection and whether this extends across the clinical spectrum (asymptomatic, mild and severe) remains unclear.

This is important for two reasons. Firstly, concomitant IBI in children hospitalized with evidence of recent or intercurrent malaria, with or without severe manifestations, results in a significantly worse outcome. In one epidemiological study an estimated one third of all SM deaths were attributable to bacteremia [5]. Secondly, it has implications when considering revisions of current management guidelines to include routine provision of antibiotics to all children with malaria. Routine antibiotics, along with anti-malarials, are currently recommended for children with SM [6]. However, malaria remains a very common cause of pediatric admission and the indiscriminate use of antibiotics would be both financially costly and could perpetuate the rise of antibiotic resistance. Thus, there remains a need for clarity on whether children with malaria are more susceptible to a bacterial infection and its precise nature in order to tailor antimicrobial management. In this systematic review we bring together the current breadth of published data on the prevalence of IBI among African children with malaria.

We reviewed published observational and epidemiological data in order to establish whether there was evidence of an association between malaria and IBI. We sought to determine the prevalence of co-infection in children with malaria infection, the risk factors for co-infection and the mortality effect in African children, drawing on this knowledge to consider the implications for future treatment guidance.


Studies were eligible for inclusion in the review if they were conducted among children with malaria, who had blood cultures taken and were admitted to hospitals or outpatient clinics in sSA. Although we restricted our review to studies reporting bacteremia, we did not exclude studies describing other bacterial co-infection, such as urinary tract infection or meningitis.

We performed a systematic search for articles describing bacterial infection among children with P. falciparum malaria. Search terms used were ‘(malaria OR plasmodium)’ AND ‘(bacteria OR bacterial OR bacteremia OR bacteraemia OR sepsis OR septicaemia OR septicemia)’ in three major scientific databases, PubMed, Embase and Africa Wide Information (AWI). The Internet search was carried out on 13 and 14 August 2012. Searches of PubMed and Embase were limited to humans while AWI was limited to humans and scholarly (peer reviewed) journals. Abstracts and titles from all years were compiled in Endnote (Thomson Reuters) and screened, after the removal of duplicates. Prospective studies were required to recruit children systematically or consecutively and to evaluate all cases. Our review was restricted to articles either written in English or translated into English. Unpublished data were not included. The protocol and review are not registered.

Eligible publications were retrieved in full text if available online or from academic libraries. Both prospective and retrospective case series of children with malaria undergoing blood culture were subdivided according to principal inclusion criteria (SM, all malaria or non-severe malaria). Studies principally reporting epidemiological associations were tabled separately. The definitions of SM varied widely. In order to facilitate agreement between the reviewers for study inclusion we used the following criteria for assessment of the quality of studies reporting on severe malaria (SM): 1) criteria for SM well-defined; 2) bacterial species defined or quality assurance verified that contaminants were excluded; 3) mortality data for ‘high risk’ SM cohort at least 7.4% (the lowest 95% confidence for artesunate arm of the AQUAMAT multicountry trial [2]; the overall mortality in this arm was 8.5% (7.4% to 9.5%)) [2]. These were ranked as low, moderate and high (1, 2 and 3) according to the number of criteria met. We reviewed the reference lists from articles rated ‘high quality’ to identify additional secondary articles not found during the initial online search.

Both authors examined the manuscripts and excluded studies during abstract review if they did not include a cohort of patients with a confirmed diagnosis of malaria, case reports, review articles or behavioral studies. During full text review, we excluded studies if they were conducted outside of sSA, did not report any microbiological data or featured predominantly adults. Studies reporting a mixed adult child population were only included if the data for children could be readily separated. Studies in which relevant data could not be extracted or where inclusion criteria failed to represent a population of children with malaria, were also excluded. For study sites generating several papers from the same study cohort, we included only the most appropriate study unless time periods varied. Data on neonates were excluded since neonates represent a group largely unaffected by malaria but with an unrelated, distinct vulnerability for IBI. We did not actively consult with specialists in the field to discuss or review.

For each study we worked out case fractions for malaria IBI co-infection as ‘number of children with malaria AND IBI’ (numerator) divided by ‘number of children with malaria’ (denominator). We used the Q test, as a measure of heterogeneity among studies, calculated as the weighted sum of squared differences between individual study effects and the pooled effect across studies. I2 was calculated to quantify heterogeneity (between-studies variability) [7]. Since the definitions for SM vary from study to study, we also compared the study inclusion criteria for SM cases with the WHO definition of SM [8].


Our search of the published literature yielded 10,200 articles and 7,897 unique articles following removal of duplicates. After reviewing the abstracts 72 full text reports were identified for closer evaluation, which were reduced to 21 studies after applying the exclusion criteria (Figure 1).
Figure 1
Figure 1

PRISMA flow diagram. Legend: nts, non-typhoidal salmonellae;, Streptococcus Pneumoniae; h. inf, Haemophilus Influenzae; s. typh, Salmonellae Typhi; gm neg, Gram negative organisms; gm pos, Gram positive organisms.

We excluded 15 studies since they described specific populations not primarily defined by malaria status. Studies alluding to an association between malaria and IBI but with incomplete information or unsuitable study design were tabulated separately (Additional file 1: Table S2). Only four studies were excluded due to location outside of sSSA, highlighting the dearth of data from other regions. Three of these studies reported predominantly data from adults [911]. A study of 340 children with severe malaria in Papua New Guinea recorded two cases of malaria with concomitant infection (invasive candida and Klebsiella Pneumoniae); however, not all children had blood cultures taken [12]. Other reasons for exclusion are detailed in Additional file 1: Table S1.

A further four papers were found from scanning reference lists of selected articles, leaving 25 studies from a total of 11 sSA countries. They comprised twenty cohort analyses (including inpatient and outpatients studies), two randomized controlled trials and three epidemiological studies, summarized in Tables 1 and 2 according to study type and clinical severity.
Table 1

Summary of 22 observational studies recording invasive bacterial infection (IBI) in children with Plasmodium falciparum malaria in sSA



Study period

Study type; primary inclusion criteria. Hospital type

Age range

Number in study

Cases with malaria Number

Cases with IBI number

Case fraction with malaria IBI co infection

Predominant organisms IBI Co-infection

Comments or associations

n/N (%)


Angyo [13]

Jos, Nigeria

Aug 92 – Oct 93


1 m-14y





SPN 34.3%

SM definition included slide negative cases (n = 214). SM mortality = 3.2%.

Severe malaria. Urban TH

S. aureus 20%

Salm spp 14.3%

Bassat [23]

Manhica, Mozambique

Jun 03 – May 07




1,404 with BC data



All EGN 36.8% NTS 15.8%

High mortality SMA and IBI (31%).

Severe malaria. Rural DH

SPN 26.3%.

Valid BC data excludes contaminants

S. aureus 17%,

Berkley [36]

Kilifi, Kenya

Apr 93 – May 96




643 with BC data



SPN 30%

Bacteremia less prevalent in >30 m (2.5%).

S. aureus 16%

Severe malaria. Rural DH

NTS 14%

Berkley [24]

Kilifi, Kenya

Aug 98 – Jul 02







EGN at high parasite counts >50,000

Mortality strongly correlated with IBI (but not with SPN and HIb).

Severe malaria. Rural DH

Case fatality inversely related to parasitemia.

Bronzan [38]

Blantyre, Malawi

1996 - 2005


>6 m





NTS 58%

Invasive NTS assoc with severe anemia (73% of NTS cases). Not associated with mortality.

(Rainy seasons)

Severe malaria. Urban RH

SPN 11%

Dorndorp [2]


Oct 05 –



5,425 Slide +/or

657 with BC data




60% children received antibiotics.


Jul 10

Severe malaria.


RDT + ve


Multi center

Kenya DRC






Enwere [39]

Banjul, Gambia


RCT; Cerebral malaria



276 with BC data



S. aureus 42.9%

Possible contaminants. High survival rate without antibiotic treatment.

(BCS ≤2) Urban TH

EGN 28.6%

Evans [22]

Kumasi, Ghana



4 m-11y


182 with BC data



NTS 43%

OR for IBI 3.5 (95% CI 1.4-8.2). No positive association of SM and bacteremia.

Pub 2004

Severe malaria. Urban TH

S.aureus 39%

E.coli 4%

Kremsner [42]

Lambarene, Gabon


PCS; sub-analysis of Abx trial; Severe malaria

>6 m


59 with



S. aureus (3) 42.9%

Addition of clindamycin to quinine shortened disease course

Pub 1995

Rural DH


BC data


EGN (2) 28.5%

Prada [43]

Lagos, Nigeria

May 92 – Aug 92

PCS; Cerebral malaria

4 m-6y





All EGN 75%

Hemolytic activity detected in 50% of bacterial strains analyzed

Urban TH

Salmonella 25%


Akinyemi [44]

Lagos, Nigeria

Oct 04 – Sept 05

PCS; Febrile illness.






S. tyhpi 45.2%

Only salmonella isolates reported. Included adults Child results reported here (unless indicated).

S. enteritidis 24.2%

2 urban RHs & 2 urban clinics


(Incl adults)

Akpede [40]

Benin, Nigeria

Oct 88 – Oct 89


1 m-5y





S. aureus 39.5%

Reanalysis of data. Retracted original suggestion of association of IBI and malaria. Note case fraction of IBI in malaria inaccurate (non-malarial febrile illness not differentiated)

Signs of febrile illness


EGN 23.2%

Urban TH

Bahwere [25]

Lwiro, DRC

Jan 89 – Dec 90







All patientsb

Positive malaria film and anemia (Hb < 8) associated with higher IBI case fraction

All hospital admissions. Rural DH


NTS 36.5%,

E. coli 15.1%, Citrobacter 6.3%

Berkley [52]

Kilifi, Kenya

Feb 99 – Dec 01






157/5,270 (3.0%)


Source data (Berkley 2009) [24]

All hospital admissions. Rural DH

1/9 with syndrome indicating Abx Rx had IBI.

Mabey [26]

Fajara, Gambia

Jan 79 – Oct 84







NTS 69.8%

Seasonal association of iNTS with malaria. NTS rare (3%) in kids >4y. iNTS more common in malaria season.

All hospital admissions. Rural DH

incl recent malaria


S. typhi 11.6%

Mtove [45]

Muheza, Tanzania

Mar 08 – Feb 09


2 m-14y





All patientsb

Invasive NTS more likely to have malaria, recent malaria, anemia, low glucose

Febrile illness + ≥1 severity criteria.

incl RDT + ve


NTS 29%

E. coli 17%

Rural DH

S. typhi 9%

Nadjm [5]

Muheza, Tanzania

June 06 - May 07


2 m-13y




100/2,195 (4.6%)

NTS 52%

>50% organisms not susceptible to 1st line Abx. Case fatality non-malaria IBI = 19%

Fever in last 48 h.

Rural DH

Okwara [20]

Nairobi, Kenya

Jan 01 – Mar 01


3 m-12y





Any GNR 62.5%

Also examined urinary isolates. 60% malaria dx in non-endemic area

Febrile Illness.


NTS 34.4%

Urban TH

Sigauque [71]

Manhica, Mozambique

May 01- April 06






621/10,699 (5.8%)

All patientsb

Almost half of the community acquired bacteremias had concomitant malaria

All hospital admissions. Rural DH

NTS 26%

SPN 25%

S. aureus 12%

E. coli 10%

Were [41]

Siaya, Kenya

Mar 04 – Jan 06

PCS; Malaria admissions;

1 m-36 m





NTS 42.3%

Proportion of IBI decreased with increasing parasitemia. Excluded previous hospitalization and CM.


S. typhi 37%;

Rural DH

S. aureus 35.6%


Ayoola [27]

Ibadan, Nigeria

Jun – Nov 98


1 m-12 m





Gram pos 56%

Excluded SM and if history of antibiotic use in preceding 7 days

Fever. Urban TH


Gram neg44%

Brent [28]

Kilifi, Kenya

May 03 – Oct 03

PCS; Unselected outpatient attendees.






All patientsb

Recruitment outside of malaria season. Excluded children with recent admission (10 days)

Rural DH


SPN 50%

aStudy population may have included neonates - unable to extract information from the text; bmicrobial prevalences refer to all study patients (not only those with malaria and IBI). Abx, antibiotic; BC, blood culture; CAB, community acquired bacteremia; CCS, cross sectional survey; DH, district hospital; MH, mission hospital; NR, not reported; PCS, prospective case series; RCS, retrospective case series; RCT, randomized controlled trial; RDT, rapid (malaria) diagnostic test; RH, referral hospital; Rx, treatment; TH, teaching hospital. Organisms: EGN, enteric gram negatives; GN, gram negative organisms; GPO, gram positive organisms; HIb, Haemophilus influenzae Group B; NTS, non-typhoidal salmonellae; Salm spp, salmonellae species; SPN, Streptococcus pneumoniae. Malaria definitions: IC, impaired consciousness; RD, respiratory distress; SMA, severe malaria anemia.

Table 2

Epidemiological studies reporting the incidence of malaria and IBI infection over time




Study period

Study type; primary inclusion criteria


Change in incidence of malaria BSI

Change in incidence of IBI Per 100,000 person years

Case-fraction of IBI co-infection

Predominant organisms for IBI co-infection


Mackenzie [32]

Fajara and Basse, Gambia

1979 – 2008 Multiple time points

Retrospective comparative case series; 4 data sets: BC taken from unwell children or suspected IBI. Routine malaria slides for febrile children

Most <5y

% Malaria in febrile children

Fajara: 60 to 10 (1979 to 2005)



NTS declined in parallel with malaria but pneumococcal bacteremia did not.

Fajara: 33% to 6% (1999 to 2007)

Basse: 105 to 29 (1989 to 2008)

Basse: 45% to 10% (1992 to 2008)

Mtove [33]

Muheza, Tanzania

2006 – 2010

Cumulative data from three prospective case series; Severely ill febrile children

2 m-14y

547 to 106/100,000 person years

Overall from

167/1,898 (8.8%)

All patients a

Severe malaria only. S. typhi most common in older age group (5-14y), and increased with decreasing malaria.

184 to 60:

NTS 34%

NTS: 82 to 7

SPN: 34 to 7

HIb: 21 to 4

S. typhi: 7 to 15

Scott [31]

Kilifi, Kenya

1999 - 2009

Case control and longitudinal study; Cases: hospital admissions with bacteremia. Controls: children born in study area.


28.5 to 3.45/1,000 person years

2.59 to 1.45/1000 person years


All patients in matched case–control study a

Reduction in protection afforded by HbAS in parallel (P = 0.0008). 62% bacteremia cases attributable to malaria

All GNs 33.2%

SPN 38%

NTS 20.9%

amicrobial spectra refer to all study patients (not only those with malaria and IBI) } Abx, antibiotic; BC, blood culture; CAB, community acquired bacteremia; CCS, cross sectional survey; DH, district hospital; IBI, invasive bacterial infections; HbAS, Sickle cell trait MH, mission hospital; NR, not reported; PCS, prospective case series; RCS, retrospective case series; RCT, randomized controlled trial; RDT, rapid (malaria) diagnostic test; RH, referral hospital; Rx, treatment; TH, teaching hospital. Organisms: EGN, enteric gram negatives; GN, gram negative organisms; GPO, gram positive organisms; HIb, Haemophilus influenzae Group B; NTS, non-typhoidal salmonellae; Salm spp, Salmonellae species; SPN, Streptococcus pneumoniae.

Evidence of IBD co-infection in malaria

Table 1 summarizes the data from 22 studies reporting the incidence of bacteremia in children with malaria in sSA, subdivided according to malaria case definition (severe malaria, all-severity malaria and non-severe). Information on location, study period, hospital type, case fraction of malaria-IBI, predominant organisms causing IBI and mortality data is included. In total, 21 studies described hospitalized inpatients and 14 were conducted prospectively.

Severe malaria

The first section of Table 1 summarizes the details of the 10 studies reporting data on children admitted with severe malaria over the period 1992 to 2010 from 15 centers in 11 sSA countries. In total, these involved 7,208 children, including 461 with concomitant IBI, mean case fraction 6.4% (95% confidence interval (CI) 5.81 to 6.98%). Eight studies involved children with all types of severe malaria, including one randomized controlled trial, whereas two only included children with cerebral malaria. With one exception [13], all studies used a positive blood slide as part of their severe malaria definition. The data from these 10 studies are summarized in Table 3, together with an assessment of the study quality. The case fraction with IBI varied according to study quality from 6.01% (95% CI 5.27 to 6.74) in the highest ranked studies including 256 bacteremias in 4,261 cases to 8.2% (95% CI 5.92 to 24.26%) involving 50 bacteremias in 610 children in the lowest ranked studies (Table 3). The Q test and I2 statistic were 40.1 and 77.5, respectively, indicating substantial heterogeneity and between-study variability; thus, a formal meta-analysis was not performed. Of note, other studies, not included in this table, described other bacterial infections (pneumonia [14, 15], meningitis [1618] and urinary tract infections [1921]) complicating malaria. Only three studies included information on a non-malaria comparator group [2224].
Table 3

Quality assessment of studies describing children with severe malaria (SM) and concomitant invasive bacterial infection (IBI) with calculated case fractions and case fatality rates


Study inclusion criteria for severe malaria compared to WHO definitiona

N with IBI data

% without IBI data

Overall mortality rate


Case fraction (%) with IBI

Case fatality malaria with concomitant IBI (%)

Case fatality malaria without IBI (%)

Overall rating of study quality


severe malaria (%)


(95% CI)

Berkley [16]

IC or RD + parasitemia (one slide) Excludes SMA without IC or RD



89/783 (11.4%)


6.53 (4.56-8.51)

14/42 (33%)

52/498 (10%)



Berkley [24]

IC or RD or SMA + parasitemia (any of three slides)



76/861 (8.8%)


6.2 (5.12-7.73)

36/127 (28%)

137/1921 (7.1%)



Bronzan [38]

WHO plus asexual parasitemia (slide repeated six hrly). Clinical signs do not include RD



235/1,388 (16.9%)


4.61 (3.48-5.74)

14/64 (22%)

211/1324 (16%)



Evans [24]

WHO definition plus asexual parasitemia (one slide)



16/182 (8.8%)


12.64 (7.47-17.8)

2/23 (8.7%)

14/159 (8.8%)







416/3,224 (12.9)


6.01 (5.27-6.74)


Bassat [23]

WHO signs (incl glucose <2.2 mmol/L) + asexual parasitemia (one thick film)



81/1,648 (4.9%)


5.41 (4.2-6.63)

13/59 (22%)

50/1244 (4.0%)



Dondorp [2]

WHO definition plus RDT positive; requiring parenteral treatment


NR (88%) (BC data not available in all patients)

527/5,425 (9.7%)


9.89 (7.49-12.3)





Enwere [39]

Cerebral malaria (BCS < =2) plus asexual parasitemia)


52% (BCx data not consecutive)

122/576 (21.1%)


5.07 (2.42-7.73)

1/14 (7.1%)

121/562 (22%)








6.63 (5.59-7.68)


Angyo [39]

Clinical signs also include hypoglycemia; shock; DIC; acidosis; hemoglobinuria. Did not include confirmed parasitemia.



16/501 (3.2%)


6.99 (4.67-9.30)





Kremsner [42]

Clinical signs also include hyperparasitemia, glucose <2.2. Excludes children with Sickle Cell disease.


41% (BCx data not consecutive)

2/100 (2%)


11.86 (3.08-35.1)

1/7 (14%)

0/52 (0%)



Prada [43]

Cerebral malaria only (not defined)





16.0 (4.91-27.09)










8.2 (5.92-24.26)


Overall total





6.40 (5.81-6.98)






aWHO Definition = clinical symptoms suggestive of SM according to WHO guidelines which includes children with the following symptoms or signs: 1) a Blantyre coma score (BCS) of two or less; 2) severe anemia with a hemoglobin level <5 g/dl or a hematocrit <15%; 3) severe respiratory distress, being marked in-drawing of the lower chest wall or deep (acidotic) breathing; and 4) prostration, being the inability to sit upright in a child able to do so, or to drink in the case of children too young to sit. Ranking is based on: 1) criteria for SM clearly defined; 2) bacterial species defined and contaminants excluded; and 3) mortality rate >7.4% (lowest CI in AQUAMAT) for SM cases. High = YYY, Moderate = YYN/YNY/NYY; Low = NNY/NYN/YNN for each of the criteria. BC, blood culture; NR, not reported; RDT, rapid (malaria) diagnostic test; Malaria definitions; IC, impaired consciousness; RD, respiratory distress; SMA, severe malaria anemia.

All severity malaria: hospital studies

The second section of Table 1 summarizes data from another 10 studies that were largely prospective studies of febrile children admitted to health facilities. In total, these 10 studies included 20,889 children with malaria and 27,641 children with non-malarial febrile illness as a comparator group (eight studies only). Bacterial infection was present in 1,166 children with malaria, 5.58% (95% CI 5.50 to 5.66), and 2,148 children without malaria, mean case fraction 7.77%, (95% CI 7.72 to 7.83%). In six out of eight studies with comparator groups, bacteremia was more common in the non-malarial febrile children (Table 4). Based on the eight studies concurrently reporting prevalence of IBI in 20,323 children hospitalized with malaria (n = 1,102; 5.4%; (95% CI 5.3 to 5.5) and 27,641 children with non-malarial febrile illness (n = 2,148; 7.77%) (Table 4), we derived a malaria attribution case fraction (MAF), indicating that children with malaria were less likely to have IBI than children with other causes of febrile illness (MAF = -2.35%). Two studies reported a higher case faction of malaria co-infection than non-malarial febrile illness in the Democratic Republic of the Congo (DRC) [25] (24.7% versus 13.0%) and in the Gambia (10.1% versus 1.97%) [26]. The latter study also included recent cases of malaria (defined as the presence of P. falciparum gametocytes and/or pigment on a blood film). However, interpreting data from these studies, which used hospitalized children with non-malarial febrile illness as a comparator group, one must consider the possibility of selection bias. If the threshold for admission in children with confirmed malaria is lower, whereas children with a non-malarial febrile illness require one or more manifestations of severe disease in order to be hospitalized, the groups may no longer be appropriately matched for comparison.
Table 4

Comparison of IBI in both malaria and non-malaria paediatric hospital admissions




Malaria case fraction with IBI

Non-malarial illness

Non-malarial illness/IBI

Non-malaria case fraction with IBI

Malaria attributable fraction of IBI

Case fatality malaria

Case fatality malaria/IBI





Akinyemi [44]









Akpede [40]








9/403 (2.2%)

3/43 (7.0%)

Bahwere [25]










Berkley [52]








110/1,143 (9.6%)

27/83 (32.5%)

Mabey [26]










Mtove [45]










Nadjm [5]








76/2,051 (3.7%)

13/100 (13%)

Okwara [20]










Sigauque [69]










Were [41]








2/447 (0.4%)

2/59 (3.4%)




5.58% (95% CI 5.34-5.50)



7.77% (95% CI 7.72-7.83)


197/4,044 (4.9%)

45/285 (15.8%)

aCalculation of total case fraction excludes data from studies without non-malaria comparator group (that is, Akinyemi(43) and Were(40)). IBI, invasive bacterial infections.

Non-severe malaria: outpatient studies

Two prospective studies (final section Table 1) describing children with non-severe malaria and concomitant IBI who did not require admission [27, 28] reported vastly different case fractions of IBI (16 of 47 (34%) versus 7 of 480 (1.5%), respectively. The scarcity of this type of study in describing IBI reflects the absence of blood culture data in children in the outpatient setting.

Other studies

Several case series, reporting prevalence and etiology of community-acquired bacteremias, have also inferred a relationship between malaria and IBI by reporting the incidence of malaria parasitemia in children with bacteremia (see Additional file 1: Table S1). In a Rwandan study, 27% of children with community-acquired bacteremia had concomitant parasitemia [29]. Malawian children with NTS bacteremia were significantly more likely to have coincident malaria and anemia than children infected with other organisms [30].

Epidemiological studies

Three studies (see Table 2) describe and analyze data from regions in sSA where a decline in malaria burden has been paralleled by a fall in the incidence of IBI. A longitudinal case–control study in Kenya, examining host protection against bacteremia involving 1,454 cases (sickle cell trait) and 10,749 controls [31] showed that at the beginning of the study, when malaria transmission was meso-hyperendemic (mean community parasite prevalence was 29%), the bacteremia incidence rate ratio associated with malaria parasitemia was 6.69 (95% CI 1.31 to 34.3)] in children three-months- to thirteen-years-old. At this time, 62% (8.2 to 91) of bacteremia cases occurred in children with malaria infection, and sickle cell trait (HbAS) was found to be strongly protective against hospital-admission with bacteremia. Over the nine-year period, as the incidence of admission to hospital with malaria per 1,000 child-years decreased from 28.5 to 3.45, a parallel reduction in protection afforded by HbAS against bacteremia was observed. The largest reduction was in the incidence of NTS bacteremia, which was mirrored by a similar reduction in the protective effect of sickle cell trait against this organism.

In separate sites in the Gambia (Fajara and Basse) at three and four time points between 1979 and 2008, the incidence of NTS infections in children was compared to both the proportion of malaria-positive thick blood films in outpatients and the percentage of malaria admissions (Fajara only) [32]. NTS incidence declined in parallel with a reduction in the incidence of malaria. While this observation may have resulted from an overall improvement in health care in the study area, increased community use of antimicrobials or methodological bias, a similar effect was not demonstrated for invasive pneumococcal disease. Similarly, in Tanzania a decline in malaria transmission was also associated with declines in all-cause bacteremia, largely driven by an 11-fold reduction in NTS [33]. However, the Phase III muticenter RTS,S vaccine trial, involving 15,460 children six-weeks- to seventeen-months-old in seven African countries, showed that the RTS,S/AS01 achieved 35% effectiveness against severe malaria but did not show an effect on all-cause bacteremia [34].

Mortality in malaria with concomitant IBI

In general, African children hospitalized with bacteremia have a poor prognosis [35]. The outcome of children co-infected with malaria and IBI also appears to be worse than cases of SM alone. Six studies reported mortality in children with SM with and without invasive bacteremia (Table 3). Together there were 81 fatalities, 24.1% (95% CI 18.86 to 29.36) in 336 children with malaria/IBI co-infection compared to 585 deaths in 5,760 children with malaria infection alone, 10.2% deaths (95% CI 9.33 to 10.98).

One prospective study of children admitted with clinical features of SM included 182 film-positive children: 23 had bacteremia (12.6%) and 2 of these died (8.7%) compared to 69 slide-negative children where 28 (41%) had bacteremia and of these 11 died (39.2%). Overall, morality was greatest in children younger than 18 months [22]. Other studies did not report mortality data by age group.

A retrospective study including 783 Kenyan children with SM showed a three-fold increase in mortality (10.4% to 33.3%) in those with IBI compared to those without IBI (P <0.001) [36]. A similar threefold increase in mortality was shown in Tanzanian children with malaria and concomitant gram-negative bacteremia [37]. The association between gram-negative organisms (especially NTS bacteremia) and mortality was reinforced by similar findings in Kenyan children [24]. In Mozambique, mortality in children with malaria and IBI co-infection increased from 4% to 22% (P <0.0001) [23]. Conversely, studies reported from Malawi and The Gambia found no relationship between malaria/IBI co-infection and increased mortality [38, 39].

Only four of the ten studies reporting case series of febrile children with all severity malaria included data on case fatality rates for both malaria and malaria/IBI groups [5, 35, 40, 41] (see Table 4). As with SM, case fatality was again higher in those co-infected with IBI. Overall, there were 45 deaths in 285 children with malaria/IBI (15.8%) compared to 197 deaths in 4,044 children with malaria alone (all forms) (4.9%). One study reported no association between IBI and all severity malaria [40]; however, 43% of all bacterial isolates in this study (including children with non malaria fevers) were due to Staphyloccocus aureus, compared to only 3% due to Streptococcus pneumoniae and, thus, may be not representative due to the possibility of contamination. Were et al. [41] reported a six-fold higher case fatality rate in malaria/IBI co-infection compared to malaria alone; however, since case fatalities were few, in total only 4 in 585 (0.7%) cases of severe malaria, this association was not significant. The study in Muheza, northeast Tanzania, describes 3,639 children admitted to a district hospital with febrile illness, where IBI increased mortality irrespective of the presence of parasitemia [5].

Microbiological spectrum of IBI

Overall, 16 of the 22 studies in Table 1 report the prevalence and spectrum of pathogenic bacteria in children with malaria infection. Taken together for children with severe malaria five of eight studies found overall that the prevalence of Gram positive organisms exceeded that of Gram negative organisms. In three studies S. aureus was the major pathogen isolated [39, 40, 42] and in two studies >35% of isolates were S. aureus [22, 41]. Overall, seven of fourteen hospital-based studies reporting specific microbiological data listed NTS as the most commonly cultured organism in children with malaria, with the large majority being Enteritidis and Typhimurium serovars [5, 20, 22, 26, 38, 41, 43]. This increased to eight studies if all EGNOs were considered [23]. Salmonellae Typhi was reported in isolated cases, predominantly in older children [26, 44, 45], with the majority of studies reporting no occurrence of S. typhi.

Comparing the proportion of NTS in malaria versus non-malaria infection we found that two of three SM studies with a comparator non-malaria cohort recorded a higher proportion of NTS bacteremia in the malaria group [23, 24]. Of the studies reporting all malaria cases, two of three studies showed higher proportions of EGNOs in malaria compared to non-malaria infections [5, 26] but NTS case numbers were only reported in one study [26]. NTS was strongly associated with recent malaria [5], which has been reported in other cohorts [46].

Among Gram-positive organisms, S. pneumoniae is the most common cause of IBI in children in Africa [4]. However, consensus appears to be lacking in the studies we reviewed since some studies indicate frequent co-infection with malaria [13, 23, 36, 47] but others do not [5, 22, 24]. A higher prevalence of HIV and the low frequencies of sickle cell carriage in certain populations may explain these regional differences [23]. In eight studies, S. aureus featured as a common culture isolate in children with malaria, exceeding 35% of all isolates in five of these studies; however, there were no suggestions of a focus of infection and contamination remains a possibility.

One study has reported the case fatality of malaria complicated by Gram-positive bacteremia to be substantially lower than mortality in malaria complicated by Gram-negative bacteremia (17.2% versus 45.7%, respectively) [37]. Case fatality of the children with NTS and EGNO bacteremia appeared to be greater than other commonly isolated invasive bacterial pathogens (range 0 to 47%); however, only one study [22] made the comparison of NTS case fatality in malaria versus non-malaria groups.

Clinical manifestations associated with malaria and concomitant IBI

A number of in-hospital studies have examined clinical manifestations associated with IBI co-morbidity, including age, SM clinical phenotype, malaria endemicity, hyperparasitemia, and underlying illness [5, 2225, 38, 41, 43, 46]. Tanzanian infants (<20 months) had higher rates of IBI co-infection (12%), particularly those <6 months old (18.5%), compared to older age groups (7.8%) [36]. A similar prevalence (15.7%) has been reported in Nigerian infants (>1- to 12-months-old) with malaria, with E. coli being the most common organism (36% of all organisms) [27]. IBI co-infection is also more commonly reported in areas of high malaria transmission. In an area of low transmission intensity, such as the island of Zanzibar, the incidence of concomitant IBI appears to be low (0.4%) and none had NTS [47]. The evidence surrounding hyperparasitemia as a co-factor for IBI susceptibility is inconclusive. Among children with SM and IBI in Kilifi, Kenya, 74% had hyperparasitemia (>10,000 uL) [36]. In Muheza, Tanzania, a third of children with malaria and IBI co-infection had high parasite densities [5]. In Western Kenya and Mozambique however, children with malaria and IBI (with EGNOs) were significantly more likely to have lower parasite densities [23, 41].

The clinical phenotype of SM appears to be an important factor. Nigerian and Gambian children [39, 43] with cerebral malaria rarely had bacterial co-infection. In Kenyan children, no association was found between the prevalence of IBI and depth of coma score [36]; whereas there was a higher case fraction with IBI in children presenting with deep breathing (a putative clinical marker of metabolic acidosis) [36]. Three studies reported that severe malarial anemia (SMA) phenotype [23, 38, 41] had a higher case fraction with IBI than other clinical manifestations of SM, which was also reported in studies involving all malaria [5, 25, 26] and this association was largely due to NTS co-infection [26, 46, 48]. In Malawi, compared to children with cerebral malaria (3.0%), those with SMA had a higher prevalence of IBI co-infection (11.7%), largely NTS bacteremia [38]. Of note are independent studies of NTS, conducted at the same hospital in Malawi and in Muheza, Tanzania, which described a positive association with both acute or recent malaria infection and anemia [45, 48]. Similarly, in Kenyan children, three quarters of patients with NTS bacteremia complicated by anemia had evidence of a recent or current malaria infection [46].

While there is enormous epidemiological potential for co-occurrence of malaria infection, malnutrition and HIV in much of sSA, the limited data available do not support such an association. Concomitant IBI was more common in underweight children (Z-score < -2) [41] and higher parasite densities were noted in Kenyan children who were HIV positive [24]. Other studies, possibly due to limited sample size were unable to demonstrate a significant association between malaria complicated by IBI and malnutrition or HIV [37, 38]. One possible explanation for a lack of association is that immunocompromised HIV-infected children may be protected from infection by the combined antimicrobial and antiparasitic properties of prophylactic co-trimoxazole [49].

Simple clinical criteria proposed by Nadjm et al. [5] identified 85% of malaria cases with culture-proven bacteremia. The Teule criteria included all of the following: current axillary temperature >38°C or <36°C, a positive rapid diagnostic test (RDT) or blood film for malaria, and one or more of: prostration; respiratory distress; severe anemia (hemoglobin <5 g/dL), or HIV infection.


Collated data examining the potential biological relationship between malaria and invasive bacterial infection across a range of studies conducted in sSA is by no means conclusive. For SM the case fraction of children with IBI co-infection was 6.4% (95% CI 5.81 to 6.98%) but with substantial between-study variability, mostly due to differences in study methodology including the case definition of SM. In prospective studies of febrile children admitted to health facilities with all-severity malaria, the case fraction with IBI was lower in children with malaria (5.6%) compared to non-malaria febrile illness (7.8%). For children with all-severity malaria (including recent infection) NTS was more commonly isolated than in non-malarial febrile illness. Added to this, several large studies [5, 24] provide further support that EGNO (including NTS species) bacterial isolates are more common in children with malaria compared to non-malaria illness, but this finding was not universal. In children with SM neither those with cerebral malaria nor children with neurological complications appeared at increased risk of IBI; however, a higher proportion of children with SMA had IBI, principally NTS. Children with malaria and IBI infection had a substantially higher mortality (22%), compared to those without (12%). However, the most compelling data on the predisposition of malaria-exposed children to IBI comes from longitudinal studies capturing declining risk of IBI, spectrum of IBI organisms and risk of mortality in parallel to an epidemiological transition from high to low malaria endemicity. The largest reduction was in the incidence of NTS bacteremia, which was mirrored by a similar reduction in the protective effect of sickle cell trait against this organism. The data we have collated from hospital cohort studies corresponds with the findings reported in epidemiological studies but is less conclusive.

Teasing apart the association between malaria and IBI has been challenging for several reasons. Foremost, both malarial parasitemia and IBI are common in children presenting with fever in malaria endemic areas. Rainy seasons in the tropics predispose to blood borne infection with enteric pathogens as well as malaria outbreaks [50, 51]. Hospitalized children often have overlapping etiological syndromes [52], for example, 27% of Mozambican children with radiologically confirmed pneumonias also had confirmed asexual parasitemia [30]. The limitations imposed by the lack of routine high quality microbiology services in sSA have resulted in a fragmented and patchy understanding of this association and its importance. Hard to culture pathogens, such as NTS [53], may be under-reported, conversely contamination remains a possibility in those studies reporting high incidences of staphylococcal organisms [27, 39, 40, 42] and requires substantiating by further studies.

The findings of this review are subject to methodological limitations. Heterogeneity was high between studies. Only a few papers recorded sufficient data to allow standardization of populations. Inclusion of recent malaria infection, using antigen-based rapid diagnostic tests, has shed more light on the prevalence of co-infection and needs further investigation. We were also unable to control for differences in study design and quality of microbiological data. For many studies, the prevalence of IBI co-infecting malaria was not the primary question, making a formal meta-analysis potentially misleading. Unpublished data were not included and, therefore, our findings may have a publication bias towards studies that report high level of concordance. In children with SM the strength of a biological association with IBI is even more difficult to establish due to the paucity of data from an appropriate control population with severe life threatening illness. Our findings do, however, concur with the conclusions of the systematic review and meta-analysis of community acquired bacterial infection indicating co-infection in 6.5% of children with malaria (any type) [4].

A putative clinical association between malaria and IBI was first suggested in the 1920s in Guyana by Giglioli who observed both increased prevalence and virulence of paratyphoid fever during malaria seasons with a co-infection rate of 29% [54]. A similar rise in typhoid fever in Nigerian children during the rainy season was speculated to be linked to the increased incidence of malaria [55]. These observations of seasonal concurrence of NTS infection and malaria were further explored in Gambian children [26] showing that while stool carriage of NTS remained constant throughout the year, rises in invasive NTS infections occurred in parallel to the annual rise in malaria cases.

The propensity for co-infection with EGNOs has led to speculation that the source of the microorganisms is most likely to be from the intestine due to impaired gut barrier function [56]. A recent mouse experiment may help our understanding of the reasons why children with malaria maybe more susceptible to concomitant NTS at the biological level [57]. The production of hemoxygenase (HO-1), which is induced in response to malaria hemolysis, resulted in impaired defense by mice towards NTS infection. While not yet replicated in humans the underlying mechanisms and portal of entry of pathogens into the bloodstream include either, or a combination of, mechanical and immune-suppressive factors. Histopathological studies have demonstrated intense sequestration of P. falciparum-infected erythrocytes within the endothelial bed of the gut, particularly at the tip of intestinal villi [58, 59]. The presence of small bowel intussusceptions in children with SM [60] has also been reported. The intense sequestration of late stage infected erythrocytes in venules and capillaries as well as the increased rigidity (or non-deformability) of non-parasitized red cells [61] both compromise microcirculatory flow to vital organs and alter endothelial cell function [62]. This may precipitate injury and impaired gut barrier function either directly or indirectly through local cytokine production, with the subsequent transfer of endotoxin and/or pathogenic bacteria into the blood stream. We have recently shown that endotoxemia is common in SM (28%) and results in temporary immune paralysis similar to that observed in patients with sepsis and experimentally-induced endotoxemia [63]. We hypothesized that the most likely origin of endotoxin was from the gut.

Although current recommendations for managing putative sepsis in children with SM are unclear [46, 64], the ideal approach is not obvious [65, 66]. For example, in one recent study almost 50% of bacterial isolates were resistant to the antibiotics most commonly recommended for empirical use by the WHO [5]. Moreover, in the specific case of NTS, the efficacy of gentamicin is doubtful and susceptibility testing unreliable due to the intracellular nature of this infection [67, 68]. For newer antimicrobials, apart from financial considerations, there are concerns that over-use could lead to resistance. Judicious use of antibiotics may prove to be critical to those at highest risk of poor outcome.


Establishing the relationship, both proof and effect, between malaria and IBI has been challenging. The accumulated evidence suggests that children with recent or acute malaria are at risk of bacterial infection, which results in an increased risk of mortality. Establishing which children with SM are at greatest risk of bacteremia would inform a policy for targeted antibiotic therapy that could substantially reduce malaria-associated mortality while minimizing the risks of excess antibiotic prescribing.

Authors’ information

JC is a Paediatric specialty trainee and Honorary Research Fellow at Queen Mary, University of London and was a visiting research fellow at the KEMRI-Wellcome research programme last year. KM is a Professor in Tropical Paediatric Infectious Diseases at Imperial College, London, based fulltime in East Africa at KEMRI Wellcome Trust Programme.



enteric gram-negative organism


invasive bacterial infection


non-typhoidal salmonella


severe malaria


severe malarial anaemia


sub Saharan Africa.



We thank Greg Fegan for statistical review.

Source of funding

Wellcome Trust Centre Grant (Imperial College).

Authors’ Affiliations

Department of Paediatrics, Faculty of Medicine, Imperial College, Wellcome Trust Centre for Clinical Tropical Medicine, St Mary’s Campus Norfolk Place, London, W2 1PG, UK
KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Department of Paediatrics, Queen Mary, University of London, Mile End Road, London, E1 4NS, UK


  1. World Health Organization: Cause-specific mortality and morbidity; causes of deaths among children. Global Health Observatory Data Repository. 2011, GenevaGoogle Scholar
  2. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T, Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J, Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A, Mokuolu OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyamboko MA, Sakulthaew T, et al: Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010, 376: 1647-1657. 10.1016/S0140-6736(10)61924-1.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Maitland K, Kiguli S, Opoka RO, Engoru C, Olupot-Olupot P, Akech SO, Nyeko R, Mtove G, Reyburn H, Lang T, Brent B, Evans JA, Tibenderana JK, Crawley J, Russell EC, Levin M, Babiker AG, Gibb DM: Mortality after fluid bolus in African children with severe infection. N Engl J Med. 2011, 364: 2483-2495. 10.1056/NEJMoa1101549.View ArticlePubMedGoogle Scholar
  4. Reddy EA, Shaw AV, Crump JA: Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis. Lancet Infect Dis. 2010, 10: 417-432. 10.1016/S1473-3099(10)70072-4.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Nadjm B, Amos B, Mtove G, Ostermann J, Chonya S, Wangai H, Kimera J, Msuya W, Mtei F, Dekker D, Malahiyo R, Olomi R, Crump JA, Whitty CJ, Reyburn H: WHO guidelines for antimicrobial treatment in children admitted to hospital in an area of intense Plasmodium falciparum transmission: prospective study. BMJ. 2010, 340: c1350-10.1136/bmj.c1350.View ArticlePubMedPubMed CentralGoogle Scholar
  6. World Health Organization: Management of severe malaria – A practical handbook. 2013, Geneva, 83-3Google Scholar
  7. Neyeloff JL, Fuchs SC, Moreira LB: Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes. 2012, 5: 52-10.1186/1756-0500-5-52.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Severe falciparum malaria. World Health Organization, communicable diseases cluster. Trans R Soc Trop Med Hyg. 2000, 94: S1-S90.Google Scholar
  9. Pattanaik SS, Tripathy R, Panda AK, Sahu AN, Das BK: Bacteraemia in adult patients presenting with malaria in India. Acta Trop. 2012, 123: 136-138. 10.1016/j.actatropica.2012.04.001.View ArticlePubMedGoogle Scholar
  10. Tripathy R, Parida S, Das L, Mishra DP, Tripathy D, Das MC, Chen H, Maguire JH, Panigrahi P: Clinical manifestations and predictors of severe malaria in Indian children. Pediatrics. 2007, 120: e454-e460. 10.1542/peds.2006-3171.View ArticlePubMedGoogle Scholar
  11. Anderson KE, Joseph SW, Nasution R, Sunoto , Butler T, Van Peenen PF, Irving GS, Saroso JS, Watten RH: Febrile illnesses resulting in hospital admission: a bacteriological and serological study in Jakarta, Indonesia. Am J Trop Med Hyg. 1976, 25: 116-121.PubMedGoogle Scholar
  12. Manning L, Laman M, Law I, Bona C, Aipit S, Teine D, Warrell J, Rosanas-Urgell A, Lin E, Kiniboro B, Vince J, Hwaiwhanje I, Karunajeewa H, Michon P, Siba P, Mueller I, Davis TM: Features and prognosis of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed Plasmodium species in Papua New Guinean children. PLoS One. 2011, 6: e29203-10.1371/journal.pone.0029203.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Angyo IA, Pam SD, Szlachetka R: Clinical pattern and outcome in children with acute severe falciparum malaria at Jos University Teaching Hospital, Nigeria. East Afr Med J. 1996, 73: 823-826.PubMedGoogle Scholar
  14. English M, Punt J, Mwangi I, McHugh K, Marsh K: Clinical overlap between malaria and severe pneumonia in Africa children in hospital. Trans R Soc Trop Med Hyg. 1996, 90: 658-662. 10.1016/S0035-9203(96)90423-X.View ArticlePubMedGoogle Scholar
  15. Sigauque B, Roca A, Bassat Q, Morais L, Quinto L, Berenguera A, Machevo S, Bardaji A, Corachan M, Ribo J, Menendez C, Schuchat A, Flannery B, Soriano-Gabarro M, Alonso PL: Severe pneumonia in Mozambican young children: clinical and radiological characteristics and risk factors. J Trop Pediatr. 2009, 55: 379-387. 10.1093/tropej/fmp030.View ArticlePubMedGoogle Scholar
  16. Berkley JA, Mwangi I, Mellington F, Mwarumba S, Marsh K: Cerebral malaria versus bacterial meningitis in children with impaired consciousness. QJM. 1999, 92: 151-157. 10.1093/qjmed/92.3.151.View ArticlePubMedGoogle Scholar
  17. Honnas A, Petersen LT: Bacterial meningitis in a rural Kenyan hospital. East Afr Med J. 1998, 75: 396-401.PubMedGoogle Scholar
  18. Wolday D, Kibreab T, Bukenya D, Hodes R: Meningococcal meningitis in patients with falciparum malaria. Trop Doct. 1996, 26: 157-159.PubMedGoogle Scholar
  19. Okunola PO, Ibadin MO, Ofovwe GE, Ukoh G: Co-existence of urinary tract infection and malaria among children under five years old: a report from Benin City, Nigeria. Saudi J Kidney Dis Transpl. 2012, 23: 629-634.PubMedGoogle Scholar
  20. Okwara FN, Obimbo EM, Wafula EM, Murila FV: Bacteraemia, urinary tract infection and malaria in hospitalised febrile children in Nairobi: is there an association?. East Afr Med J. 2004, 81: 47-51.View ArticlePubMedGoogle Scholar
  21. Uneke CJ, Alo MN: Urinary tract infections in Nigerian children with malaria. Indian J Pediatr. 2008, 75: 408-409.PubMedGoogle Scholar
  22. Evans JA, Adusei A, Timmann C, May J, Mack D, Agbenyega T, Horstmann RD, Frimpong E: High mortality of infant bacteraemia clinically indistinguishable from severe malaria. QJM. 2004, 97: 591-597. 10.1093/qjmed/hch093.View ArticlePubMedGoogle Scholar
  23. Bassat Q, Guinovart C, Sigauque B, Mandomando I, Aide P, Sacarlal J, Nhampossa T, Bardaji A, Morais L, Machevo S, Letang E, Macete E, Aponte JJ, Roca A, Menendez C, Alonso PL: Severe malaria and concomitant bacteraemia in children admitted to a rural Mozambican hospital. Trop Med Int Health. 2009, 14: 1011-1019. 10.1111/j.1365-3156.2009.02326.x.View ArticlePubMedGoogle Scholar
  24. Berkley JA, Bejon P, Mwangi T, Gwer S, Maitland K, Williams TN, Mohammed S, Osier F, Kinyanjui S, Fegan G, Lowe BS, English M, Peshu N, Marsh K, Newton CRJC: HIV infection, malnutrition, and invasive bacterial infection among children with severe malaria. Clin Infect Dis. 2009, 49: 336-343. 10.1086/600299.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Bahwere P, Levy J, Hennart P, Donnen P, Lomoyo W, Dramaix-Wilmet M, Butzler JP, De Mol P: Community-acquired bacteremia among hospitalized children in rural central Africa. Int J Infect Dis. 2001, 5: 180-188. 10.1016/S1201-9712(01)90067-0.View ArticlePubMedGoogle Scholar
  26. Mabey DC, Brown A, Greenwood BM: Plasmodium falciparum malaria and Salmonella infections in Gambian children. J Infect Dis. 1987, 155: 1319-1321. 10.1093/infdis/155.6.1319.View ArticlePubMedGoogle Scholar
  27. Ayoola OO, Adeyemo AA, Osinusi K: Concurrent bacteraemia and malaria in febrile Nigerian infants. Trop Doct. 2005, 35: 34-36. 10.1258/0049475053001840.View ArticlePubMedGoogle Scholar
  28. Brent AJ, Ahmed I, Ndiritu M, Lewa P, Ngetsa C, Lowe B, Bauni E, English M, Berkley JA, Scott JA: Incidence of clinically significant bacteraemia in children who present to hospital in Kenya: community-based observational study. Lancet. 2006, 367: 482-488. 10.1016/S0140-6736(06)68180-4.View ArticlePubMedGoogle Scholar
  29. Lepage P, Bogaerts J, Van Goethem C, Ntahorutaba M, Nsengumuremyi F, Hitimana DG, Vandepitte J, Butzler JP, Levy J: Community-acquired bacteraemia in African children. Lancet. 1987, 1: 1458-1461.View ArticlePubMedGoogle Scholar
  30. Walsh AL, Phiri AJ, Graham SM, Molyneux EM, Molyneux ME: Bacteremia in febrile Malawian children: clinical and microbiologic features. Pediatr Infect Dis J. 2000, 19: 312-318. 10.1097/00006454-200004000-00010.View ArticlePubMedGoogle Scholar
  31. Scott JA, Berkley JA, Mwangi I, Ochola L, Uyoga S, Macharia A, Ndila C, Lowe BS, Mwarumba S, Bauni E, Marsh K, Williams TN: Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case–control study and a longitudinal study. Lancet. 2011, 378: 1316-1323. 10.1016/S0140-6736(11)60888-X.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Mackenzie G, Ceesay SJ, Hill PC, Walther M, Bojang KA, Satoguina J, Enwere G, D'Alessandro U, Saha D, Ikumapayi UN, O'Dempsey T, Mabey DC, Corrah T, Conway DJ, Adegbola RA, Greenwood BM: A decline in the incidence of invasive non-typhoidal Salmonella infection in The Gambia temporally associated with a decline in malaria infection. PLoS One. 2010, 5: e10568-10.1371/journal.pone.0010568.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Mtove G, Amos B, Nadjm B, Hendriksen IC, Dondorp AM, Mwambuli A, Kim DR, Ochiai RL, Clemens JD, Von Seidlein L, Reyburn H, Deen J: Decreasing incidence of severe malaria and community-acquired bacteraemia among hospitalized children in Muheza, north-eastern Tanzania, 2006–2010. Malar J. 2011, 10: 320-10.1186/1475-2875-10-320.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmuller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Nhamuave A, Quelhas D, Bassat Q, Mandjate S, Macete E, Alonso P, Abdulla S, Salim N, Juma O, Shomari M, Shubis K, Machera F, Hamad AS, Minja R, et al: First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med. 2011, 365: 1863-1875.View ArticlePubMedGoogle Scholar
  35. Berkley JA, Lowe BS, Mwangi I, Williams T, Bauni E, Mwarumba S, Ngetsa C, Slack MP, Njenga S, Hart CA, Maitland K, English M, Marsh K, Scott JA: Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med. 2005, 352: 39-47. 10.1056/NEJMoa040275.View ArticlePubMedGoogle Scholar
  36. Berkley J, Mwarumba S, Bramham K, Lowe B, Marsh K: Bacteraemia complicating severe malaria in children. Trans R Soc Trop Med Hyg. 1999, 93: 283-286. 10.1016/S0035-9203(99)90024-X.View ArticlePubMedGoogle Scholar
  37. Blomberg B, Manji KP, Urassa WK, Tamim BS, Mwakagile DS, Jureen R, Msangi V, Tellevik MG, Holberg-Petersen M, Harthug S, Maselle SY, Langeland N: Antimicrobial resistance predicts death in Tanzanian children with bloodstream infections: a prospective cohort study. BMC Infect Dis. 2007, 7: 43-10.1186/1471-2334-7-43.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Bronzan RN, Taylor TE, Mwenechanya J, Tembo M, Kayira K, Bwanaisa L, Njobvu A, Kondowe W, Chalira C, Walsh AL, Phiri A, Wilson LK, Molyneux ME, Graham SM: Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV coinfection, and outcome. J Infect Dis. 2007, 195: 895-904. 10.1086/511437.View ArticlePubMedGoogle Scholar
  39. Enwere G, Van Hensbroek MB, Adegbola R, Palmer A, Onyiora E, Weber M, Greenwood B: Bacteraemia in cerebral malaria. Ann Trop Paediatr. 1998, 18: 275-278.View ArticlePubMedGoogle Scholar
  40. Akpede GO, Sykes RM: Malaria with bacteraemia in acutely febrile preschool children without localizing signs: coincidence or association/complication?. J Trop Med Hyg. 1993, 96: 146-150.PubMedGoogle Scholar
  41. Were T, Davenport GC, Hittner JB, Ouma C, Vulule JM, Ong'echa JM, Perkins DJ: Bacteremia in Kenyan children presenting with malaria. J Clin Microbiol. 2011, 49: 671-676. 10.1128/JCM.01864-10.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Kremsner PG, Radloff P, Metzger W, Wildling E, Mordmuller B, Philipps J, Jenne L, Nkeyi M, Prada J, Bienzle U, et al: Quinine plus clindamycin improves chemotherapy of severe malaria in children. Antimicrob Agents Chemother. 1995, 39: 1603-1605. 10.1128/AAC.39.7.1603.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Prada J, Alabi SA, Bienzle U, Kremsner PG: Bacterial strains isolated from blood cultures of Nigerian children with cerebral malaria. Lancet. 1993, 342: 1114.View ArticlePubMedGoogle Scholar
  44. Akinyemi KO, Bamiro BS, Coker AO: Salmonellosis in Lagos, Nigeria: incidence of Plasmodium falciparum-associated co-infection, patterns of antimicrobial resistance, and emergence of reduced susceptibility to fluoroquinolones. J Health Popul Nutr. 2007, 25: 351-358.PubMedPubMed CentralGoogle Scholar
  45. Mtove G, Amos B, von Seidlein L, Hendriksen I, Mwambuli A, Kimera J, Mallahiyo R, Kim DR, Ochiai RL, Clemens JD, Reyburn H, Magesa S, Deen JL: Invasive salmonellosis among children admitted to a rural Tanzanian hospital and a comparison with previous studies. PLoS One. 2010, 5: e9244-10.1371/journal.pone.0009244.View ArticlePubMedPubMed CentralGoogle Scholar
  46. Brent AJ, Oundo JO, Mwangi I, Ochola L, Lowe B, Berkley JA: Salmonella bacteremia in Kenyan children. Pediatr Infect Dis J. 2006, 25: 230-236. 10.1097/01.inf.0000202066.02212.ff.View ArticlePubMedGoogle Scholar
  47. Thriemer K, Ley B, Ame S, von Seidlein L, de Pak G, Chang NY, Hashim R, Schmied WH, BuschClara CJ, Nixon S, Morrissey A, Puri MK, Ali M, Ochiai RL, Wierzba T, Jiddawi MS, Clemens JD, Ali SM, Deen JL: The burden of invasive bacterial infections in Pemba, Zanzibar. PloS One. 2012, 7: e30350-10.1371/journal.pone.0030350.View ArticlePubMedPubMed CentralGoogle Scholar
  48. Graham SM, Walsh AL, Molyneux EM, Phiri AJ, Molyneux ME: Clinical presentation of non-typhoidal Salmonella bacteraemia in Malawian children. Trans R Soc Trop Med Hyg. 2000, 94: 310-314. 10.1016/S0035-9203(00)90337-7.View ArticlePubMedGoogle Scholar
  49. Mulenga V, Ford D, Walker AS, Mwenya D, Mwansa J, Sinyinza F, Lishimpi K, Nunn A, Gillespie S, Zumla A, Chintu C, Gibb DM: Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. AIDS. 2007, 21: 77-84. 10.1097/QAD.0b013e3280114ed7.View ArticlePubMedGoogle Scholar
  50. Enwere G, Biney E, Cheung Y, Zaman SM, Okoko B, Oluwalana C, Vaughan A, Greenwood B, Adegbola R, Cutts FT: Epidemiologic and clinical characteristics of community-acquired invasive bacterial infections in children aged 2–29 months in The Gambia. Pediatr Infect Dis J. 2006, 25: 700-705. 10.1097/01.inf.0000226839.30925.a5.View ArticlePubMedGoogle Scholar
  51. O'Dempsey TJ, McArdle TF, Lloyd-Evans N, Baldeh I, Laurence BE, Secka O, Greenwood BM: Importance of enteric bacteria as a cause of pneumonia, meningitis and septicemia among children in a rural community in The Gambia, West Africa. Pediatr Infect Dis J. 1994, 13: 122-128. 10.1097/00006454-199402000-00009.View ArticlePubMedGoogle Scholar
  52. Berkley JA, Maitland K, Mwangi I, Ngetsa C, Mwarumba S, Lowe BS, Newton CR, Marsh K, Scott JA, English M: Use of clinical syndromes to target antibiotic prescribing in seriously ill children in malaria endemic area: observational study. BMJ. 2005, 330: 995-10.1136/bmj.38408.471991.8F.View ArticlePubMedPubMed CentralGoogle Scholar
  53. Cheesbrough JS, Taxman BC, Green SD, Mewa FI, Numbi A: Clinical definition for invasive Salmonella infection in African children. Pediatr Infect Dis J. 1997, 16: 277-283. 10.1097/00006454-199703000-00005.View ArticlePubMedGoogle Scholar
  54. Giglioli G: Paratyphoid C an endemic disease of British Guiana: a clinical and pathological outline. B. paratyphosum C as a pyogenic organism: case reports. Proc R Soc Med. 1929, 23: 165-177.PubMedPubMed CentralGoogle Scholar
  55. Duggan MB, Beyer L: Enteric fever in young Yoruba children. Arch Dis Child. 1975, 50: 67-71. 10.1136/adc.50.1.67.View ArticlePubMedPubMed CentralGoogle Scholar
  56. Wilairatana P, Meddings JB, Ho M, Vannaphan S, Looareesuwan S: Increased gastrointestinal permeability in patients with Plasmodium falciparum malaria. Clin Infect Dis. 1997, 24: 430-435. 10.1093/clinids/24.3.430.View ArticlePubMedGoogle Scholar
  57. Cunnington AJ, de Souza JB, Walther M, Riley EM: Malaria impairs resistance to Salmonella through heme- and heme oxygenase-dependent dysfunctional granulocyte mobilization. Nat Med. 2012, 18: 120-127.View ArticleGoogle Scholar
  58. Olsson RA, Johnston EH: Histopathologic changes and small-bowel absorption in falciparum malaria. Am J Trop Med Hyg. 1969, 18: 355-359.PubMedGoogle Scholar
  59. Pongponratn E, Riganti M, Punpoowong B, Aikawa M: Microvascular sequestration of parasitized erythrocytes in human falciparum malaria: a pathological study. Am J Trop Med Hyg. 1991, 44: 168-175.PubMedGoogle Scholar
  60. Seydel KB, Milner DA, Kamiza SB, Molyneux ME, Taylor TE: The distribution and intensity of parasite sequestration in comatose Malawian children. J Infect Dis. 2006, 194: 208-215. 10.1086/505078.View ArticlePubMedPubMed CentralGoogle Scholar
  61. Dondorp AM, Kager PA, Vreeken J, White NJ: Abnormal blood flow and red blood cell deformability in severe malaria. Parasitol Today. 2000, 16: 228-232. 10.1016/S0169-4758(00)01666-5.View ArticlePubMedGoogle Scholar
  62. Moxon CA, Grau GE, Craig AG: Malaria: modification of the red blood cell and consequences in the human host. Br J Haematol. 2011, 154: 670-679. 10.1111/j.1365-2141.2011.08755.x. doi: 10.1111/j.1365-2141.2011.08755.xView ArticlePubMedPubMed CentralGoogle Scholar
  63. Olupot-Olupot P, Urban BC, Jemutai J, Nteziyaremye J, Fanjo HM, Karanja H, Karisa J, Ongodia P, Bwonyo P, Gitau EN, Talbert A, Akech S, Maitland K: Endotoxaemia is common in children with Plasmodium falciparum malaria. BMC Infect Dis. 2013, 13: 117-10.1186/1471-2334-13-117.View ArticlePubMedPubMed CentralGoogle Scholar
  64. World Health Organization: WHO guidelines for the treatment of malaria. 2006, Geneva: Global Malaria ProgrammeGoogle Scholar
  65. Farnert A, Gwer S, Berkley JA: Clinical considerations for antibiotic choices in the treatment of severe malaria. Trends Parasitol. 2010, 26: 465-466. 10.1016/ ArticlePubMedGoogle Scholar
  66. Maitland K: Antimicrobials in children admitted to hospital in malaria endemic areas. BMJ. 2010, 340: c1818-10.1136/bmj.c1818.View ArticlePubMedGoogle Scholar
  67. Lode H: The pharmacokinetics of azithromycin and their clinical significance. Eur J Clin Microbiol Infect Dis. 1991, 10: 807-812. 10.1007/BF01975832.View ArticlePubMedGoogle Scholar
  68. Graham SM, English M: Non-typhoidal salmonellae: a management challenge for children with community-acquired invasive disease in tropical African countries. Lancet. 2009, 373: 267-269. 10.1016/S0140-6736(09)60073-8.View ArticlePubMedPubMed CentralGoogle Scholar
  69. Sigauque B, Roca A, Mandomando I, Morais L, Quinto L, Sacarlal J, Macete E, Nhamposa T, Machevo S, Aide P, Bassat Q, Bardaji A, Nhalungo D, Soriano-Gabarro M, Flannery B, Menendez C, Levine MM, Alonso PL: Community-acquired bacteremia among children admitted to a rural hospital in Mozambique. Pediatr Infect Dis J. 2009, 28: 108-113. 10.1097/INF.0b013e318187a87d.View ArticlePubMedGoogle Scholar


© Church and Maitland; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.